Wei Li1, Tohti Amet1, Yanyan Xing1, Dennis Yang1, Suthat Liangpunsakul2,3,4, Puneet Puri5, Patrick S Kamath6, Arun J Sanyal5, Vijay H Shah6, Barry P Katz7, Svetlana Radaeva8, David W Crabb2,9, Naga Chalasani2, Qigui Yu1. 1. Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN. 2. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN. 3. Roudebush Veterans Administration Medical Center, Indiana University School of Medicine, Indianapolis, IN. 4. Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN. 5. Division of Gastroenterology and Hepatology, Department of Medicine, Virginia Commonwealth University, Richmond, VA. 6. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN. 7. Department of Biostatistics, Indiana University School of Medicine and Richard M. Fairbanks School of Public Health, Indianapolis, IN. 8. National Institute of Alcoholism and Alcohol Abuse, National Institutes of Health, Rockville, MD. 9. Internal Medicine, Eskenazi Health, Indianapolis, IN.
Abstract
Alcoholic hepatitis (AH) develops in only a small proportion of heavy drinkers. To better understand the mechanisms underlying this disparity, we conducted a study to define the relationship between AH development and dysregulated immune responses that might be ameliorated by alcohol abstinence. Sixty-eight AH patients, 65 heavy drinking controls without liver disease (HDC), and 20 healthy controls were enrolled and followed up to 12 months. At baseline, HDC and healthy controls had no significant differences in their plasma levels of 38 inflammatory cytokines/chemokines measured using multiplex immunoassays. However, compared to HDC, AH patients had higher baseline levels of 11 cytokines/chemokines (tumor necrosis factor alpha, interleukin 6 [IL-6], IL-8, interferon gamma-induced protein 10, IL-4, IL-9, IL-10, fibroblast growth factor 2, IL-7, IL-15, and transforming growth factor alpha) but lower levels of the anti-inflammatory macrophage-derived chemokine. AH patients also had more activated yet dysfunctional immune cells as monocytes, T cells, and B cells expressed higher levels of cluster of differentiation 38 (CD38) and CD69 but low levels of human leukocyte antigen DR, CD80, and CD86 at baseline. In addition, CD4 T cells produced less interferon-gamma in response to T-cell stimulation. Up-regulated IL-6, IL-8, CD38, and CD69 and down-regulated macrophage-derived chemokine, human leukocyte antigen DR, CD86, and CD80 correlated positively and negatively, respectively, with disease severity. Longitudinal analysis indicated that levels of IL-6, IL-8, CD38, and CD69 were reduced, whereas levels of macrophage-derived chemokine, human leukocyte antigen DR, CD80, and CD86 were increased in abstinent AH patients. All of the cellular immune abnormalities were reversed by day 360 in abstinent AH patients; however, plasma levels of tumor necrosis factor alpha, IL-8, IL-10, fibroblast growth factor 2, and IL-7 remained higher. CONCLUSION: AH patients were in a highly immune-dysregulated state, whereas HDC showed little evidence of immune activation; alcohol abstinence reversed most, but not all, of the immunological abnormalities. (Hepatology 2017;66:575-590).
Alcoholic hepatitis (AH) develops in only a small proportion of heavy drinkers. To better understand the mechanisms underlying this disparity, we conducted a study to define the relationship between AH development and dysregulated immune responses that might be ameliorated by alcohol abstinence. Sixty-eight AHpatients, 65 heavy drinking controls without liver disease (HDC), and 20 healthy controls were enrolled and followed up to 12 months. At baseline, HDC and healthy controls had no significant differences in their plasma levels of 38 inflammatory cytokines/chemokines measured using multiplex immunoassays. However, compared to HDC, AHpatients had higher baseline levels of 11 cytokines/chemokines (tumor necrosis factor alpha, interleukin 6 [IL-6], IL-8, interferon gamma-induced protein 10, IL-4, IL-9, IL-10, fibroblast growth factor 2, IL-7, IL-15, and transforming growth factor alpha) but lower levels of the anti-inflammatory macrophage-derived chemokine. AHpatients also had more activated yet dysfunctional immune cells as monocytes, T cells, and B cells expressed higher levels of cluster of differentiation 38 (CD38) and CD69 but low levels of human leukocyte antigen DR, CD80, and CD86 at baseline. In addition, CD4 T cells produced less interferon-gamma in response to T-cell stimulation. Up-regulated IL-6, IL-8, CD38, and CD69 and down-regulated macrophage-derived chemokine, human leukocyte antigen DR, CD86, and CD80 correlated positively and negatively, respectively, with disease severity. Longitudinal analysis indicated that levels of IL-6, IL-8, CD38, and CD69 were reduced, whereas levels of macrophage-derived chemokine, human leukocyte antigen DR, CD80, and CD86 were increased in abstinent AHpatients. All of the cellular immune abnormalities were reversed by day 360 in abstinent AHpatients; however, plasma levels of tumor necrosis factor alpha, IL-8, IL-10, fibroblast growth factor 2, and IL-7 remained higher. CONCLUSION:AHpatients were in a highly immune-dysregulated state, whereas HDC showed little evidence of immune activation; alcohol abstinence reversed most, but not all, of the immunological abnormalities. (Hepatology 2017;66:575-590).
Authors: Emilio González-Reimers; Camino M Fernández-Rodríguez; Francisco Santolaria-Fernández; María José de la Vega-Prieto; Candelaria Martín-González; M Ángeles Gómez-Rodríguez; M R Alemán-Valls; Melchor Rodríguez-Gaspar Journal: Alcohol Alcohol Date: 2011-06-02 Impact factor: 2.826
Authors: Manuela G Neuman; Yaakov Maor; Radu M Nanau; Ehud Melzer; Haim Mell; Mihai Opris; Lawrence Cohen; Stephen Malnick Journal: Biomolecules Date: 2015-08-28
Authors: John B Whitfield; Steven Masson; Suthat Liangpunsakul; Jessica Hyman; Sebastian Mueller; Guruprasad Aithal; Florian Eyer; Dermot Gleeson; Andrew Thompson; Felix Stickel; Michael Soyka; Ann K Daly; Heather J Cordell; Tiebing Liang; Tatiana Foroud; Lawrence Lumeng; Munir Pirmohamed; Bertrand Nalpas; Camille Bence; Jean-Marc Jacquet; Alexandre Louvet; Romain Moirand; Pierre Nahon; Sylvie Naveau; Pascal Perney; Philippe Podevin; Paul S Haber; Helmut K Seitz; Christopher P Day; Philippe Mathurin; Timothy M Morgan; Devanshi Seth Journal: Alcohol Date: 2017-09-23 Impact factor: 2.405
Authors: Reesha R Patel; Florence P Varodayan; Melissa A Herman; Vanessa Jimenez; Rebecca Agnore; Lina Gao; Michal Bajo; Verginia C Cuzon Carlson; Nicole A Walter; Suzanne S Fei; Kathleen A Grant; Marisa Roberto Journal: Neuropsychopharmacology Date: 2021-11-26 Impact factor: 8.294
Authors: Wei Li; Edward L Lin; Suthat Liangpunsakul; Jie Lan; Sai Chalasani; Sushmita Rane; Puneet Puri; Patrick S Kamath; Arun J Sanyal; Vijay H Shah; Svetlana Radaeva; David W Crabb; Naga Chalasani; Qigui Yu Journal: Clin Transl Gastroenterol Date: 2019-06 Impact factor: 4.488